SteadyMed’s NDA for Trevyent to Treat PAH Refused by FDA; More Information Needed
Pulmonary Hypertension
The U.S. Food and Drug Administration rejected SteadyMed’s new drug application (NDA) for Trevyent (treprostinil), a treatment for pulmonary arterial hypertension (PAH). According to the FDA’s Refusal to File letter, the ... Read more